SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ViroLogic (VLGC)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Ian@SI who wrote (22)9/11/2000 4:14:51 PM
From: Don Knowlton  Read Replies (1) of 59
 
Ian,

This study talks about the total medical treatment cost. The saving only comes in at about 5%. It would be interesting to understand the percentage savings for drugs alone. Also, assuming the company's customers are really the medical insurance companies, would 5% savings be high motivation for them to support VLGC testing or not?

I'm in the computer chip business, and 5% is not enough savings to get the attention of large customers. Due to our customers' cost to bring on a new supplier, they look for much more.

Don
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News